INGELHEIM, Germany - Monday, August 15th 2016 [ME NewsWire]
Praxbind® (idarucizumab) is the specific reversal agent for the oral anticoagulant Pradaxa® (dabigatran)1,2
Praxbind® is already available in over 5,000 hospitals worldwide and is approved in over 35 countries3
RE-VECTO will provide insights into the diverse types of situations in which reversal of an anticoagulant is performed in clinical practice
(BUSINESS WIRE)-- Boehringer Ingelheim today announces its global RE-VECTO program for Praxbind® (idarucizumab), the specific reversal agent for Pradaxa® (dabigatran etexilate).1,2 Praxbind® is approved to reverse the anticoagulant effects of Pradaxa® in rare critical care situations such as prior to emergency surgery or an urgent intervention, or in cases of life-threatening or uncontrolled bleeding.1,2 The emergency situations in which Praxbind® may be used can vary g
...
Read more »